Verteporfin mediated sequence dependent combination therapy against ovarian cancer cell line

Basit Öğe Kaydı
dc.authorid0000-0001-6876-3555
dc.authorid0000-0002-0675-1839
dc.authorid0000-0002-5919-1986
dc.contributor.authorErdem, Sultan Sibel
dc.contributor.authorAkgül Obeidin, Vildan
dc.contributor.authorYiğitbaşı, Türkan
dc.contributor.authorTümer, S. Serranur
dc.contributor.authorYiğit, Pakize
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:50:33Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:50:33Z
dc.date.issued2018
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Biyokimya Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Rektörlük, Rejeneratif ve Restoratif Tıp Araştırmaları Merkezi (REMER)
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Biyokimya Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Biyoistatistik ve Tıp Bilişimi Ana Bilim Dalı
dc.descriptionWOS: 000435049000031
dc.descriptionPubMed ID: 29747146
dc.description.abstractOvarian Cancer is one of the deadliest gynecological cancer showing high resistance to chemotherapy. Non overlapping and synergistic combination therapies are the best option to overcome this multi-pathological silent disease. Cationic peptides (CPs) with high targeting feature and ability to pass through cell membrane induce apoptosis via disruption of cancer cell membrane. Photodynamic Therapy (PDT) is a noninvasive clinically approved treatment modality combining light activated photosensitizer, light and oxygen. In this study we present, combination therapy composed of 9-mer +4 charge bearing CP and Benzoporphyrin derivative monoacid, (BPD-MA, Verteporfin) mediated PDT. In order to evaluate the effect of sequence on the outcome of the therapy, CP and BPD-MA mediated PDT was applied in two different sequence: 'CP first' BPD-MA first'. Treatment efficacy of combination therapy in SKOV-3 ovarian cancer cell line has been evaluated based on cell inhibition, cell death pathway, Combination index (CI), and Dose Reduction Index (DRI) values. When SKOV-3 ovarian cancer cell line treated with BPD-MA mediated PDT (5 J/cm (2)) and CP individually, IC30 values for each drug were determined as 1.1 mu M and 240 mu M respectively and apoptosis was the major death cell pathway for both of the drugs. In the case of combination therapy, SKOV-3 cell line treated with drugs in constant ratio yet on different sequence. Drugs were used in constant ratio so that one of them would not deemphasize the effect of other in any concentration point. Our theoretical and experimental results were in agreement and showed that the treatment outcome significantly depends on the order of the treatment. For instance, while BPD-MA mediated PDT was applied prior to CP, cell inhibition at IC30 value of BPD-MA was roughly 28% with CI = 3.3 suggesting antagonistic interaction between each therapy. When the sequence of treatment was changed to CP first, cell inhibition at IC30 concentration of CP was determined as 98% with CI = 0.3 creating substantial synergism between the drugs. Moreover, synergistic interactions were observed at all concentration points at CP first scenario. DRI value for CP first treatment option was much higher compared to BPD-MA first treatment making the former treatment sequence more attractive option for clinically relevant combination therapies. Based on our results, we strongly believe that 9-mer CP and BPD-MA-PDT based combination therapy, offering synergistic therapeutic outcome, may increase chances of treatment of ovarian cancer in comparison to 9-mer CP and/or BPD-MA alone case.
dc.description.sponsorshipScientific and Technological Research Council of Turkey, TUBITAK [215S158]en_US
dc.description.sponsorshipThe authors would like to thank Dr. Nese Altuncu for fruitful discussion to acquire microscopy images. This work was funded by The Scientific and Technological Research Council of Turkey, TUBITAK, with grand number 215S158.en_US
dc.identifier.citationErdem, S., Obeidin, V., Yiğitbaşı, T., Tümer, S. ve Yiğit, P. (2018). Verteporfin mediated sequence dependent combination therapy against ovarian cancer cell line. Journal of Photochemistry and Photobiology B-Biology, 183, 266-274. https://dx.doi.org/10.1016/j.jphotobiol.2018.04.039
dc.identifier.doi10.1016/j.jphotobiol.2018.04.039
dc.identifier.endpage274
dc.identifier.issn1011-1344
dc.identifier.scopusqualityQ1
dc.identifier.startpage266
dc.identifier.urihttps://dx.doi.org/10.1016/j.jphotobiol.2018.04.039
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2016
dc.identifier.volume183
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Sa
dc.relation.ecinfo:eu-repo/grantAgreement/TUBITAK/SOBAG/215S158
dc.relation.ispartofJournal of Photochemistry and Photobiology B-Biologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectPhotodynamic Therapy
dc.subjectCombination Therapy
dc.subjectCationic Peptide
dc.subjectVerteporfin
dc.subjectOvarian Cancer
dc.titleVerteporfin mediated sequence dependent combination therapy against ovarian cancer cell line
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Yiğitbaşı, T..pdf
Boyut:
1.08 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu